ORYZON Awarded EUR13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project) GlobeNewswire May 08, 2025 Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder […]

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists GlobeNewswire May 08, 2025 OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM's

Privia Health Reports First Quarter 2025 Financial Results GlobeNewswire May 08, 2025 Strong First Quarter Performance and Operating Execution Enters the State of Arizona Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged ARLINGTON, Va., May 08, 2025 (GLOBE NEWSWIRE) — Privia Health Group, Inc.

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire May 08, 2025 – Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 – – Expected Cash Runway Extended Through the First Half of 2028 – – Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of

ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm GlobeNewswire May 08, 2025 NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Arvinas, Inc. (“Arvinas”

Axiomise Featured Gold Sponsor at RISC-V Summit Europe Next Week in Paris GlobeNewswire May 08, 2025 Ongoing Booth Demos of Axiomise's formalISA bug hunter and footprint for end-to-end architectural verification Lightning Talk, Presentation on Benefits of Formal Verification for RISC-V Verification from Founder and CEO Dr. Ashish Darbari LONDON, May 08, 2025 (GLOBE NEWSWIRE) —

Medisafe PATHWAYS, Eisai and Biogen Recognized for Alzheimer's Disease Innovation in 2025 MedTech Breakthrough Awards Program Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies GlobeNewswire May 08, 2025 LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) — MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies,

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results GlobeNewswire May 08, 2025 – EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – — BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet,

Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2025 Outlook GlobeNewswire May 08, 2025 First Quarter Revenue was $559.2 million, a 14.0% increase over the prior year period Gross margin increased 25.9% to $183.6 million compared to Q1 2024 First Quarter Net income was $5.2 million compared to net loss of $11.2 million

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value GlobeNewswire May 08, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board